Polyphenols as acetylcholinesterase inhibitors: Structural specificity and impact on human disease

Luísa Bivar Roseiro\textsuperscript{a,b,*}, Amélia Pilar Rauter\textsuperscript{b} and Maria Luísa Mourato Serralheiro\textsuperscript{b}

\textsuperscript{a}Laboratório Nacional de Energia e Geologia – Unidade de Bioenergia (LNEG-UB), Lisboa, Portugal
\textsuperscript{b}Faculdade de Ciências, Centro de Química e Bioquímica/Departamento de Química e Bioquímica, Universidade de Lisboa, Lisboa, Portugal

Abstract. The present review focuses on the emerging evidence regarding the potential of polyphenols to act as acetylcholinesterase inhibitors. This enzyme plays a fundamental role in the body and its inhibition may play a role in the control of various pathologies, including Myasthenia gravis, Glaucoma and Alzheimer’s disease. Polyphenols are present throughout the human diet and their potential effects in ameliorating the quality of life and to prevent human ageing are the subject of numerous and varied research. In this review we outline the potential influence of polyphenols on acetylcholinesterase with a particular view to describing their actions in the brain. Following an introduction to the biochemical actions of the enzyme and its active site, we will present an overview of the reported actions of polyphenols, in particular flavonoids and tannins, to act as acetylcholinesterase inhibitors. We will also highlight structure-activity relationships and how metabolism of polyphenols during absorption affects their function. Finally, we discuss the evidence for some foods to possess acetylcholinesterase inhibitor activity.

Keywords: Acetylcholinesterase inhibitors, polyphenols, flavonoids, tannins, neurodegenerative disorders

1. Introduction

Acetylcholinesterase (AChE) is an acetylcholine hydrolase enzyme (acetylcholine acetylhydrolase E.C. 3.1.1.7) with esterase activity, localized in the synaptic gaps of the central and peripheral nervous system. This membrane bound enzyme is projected into the synapse and terminates nervous impulses by catalysing the hydrolysis of the neurotransmitter acetylcholine, a neurotransmitter of cholinergic system, which amongst other roles is involved in memory formation [1]. It is a serine hydrolase with a catalytic triad, similar to other serine proteases and, although it was isolated from Torpedo californica (TcAChE) and its 3D structure was elucidated in 1991, the role of this enzyme in several diseases was ascertained years earlier.

Acetylcholinesterase inhibitors (AChEI) are used clinically to counteract various pathologies, including Myasthenia gravis, Glaucoma, Lewy body dementia and Alzheimer’s disease [2]. Treatment is known to improve symptoms by enhancing cholinergic functions and increasing the amount of acetylcholine present in cholinergic synapses. To be effective inhibitors must reversibly bind to the active site of the enzyme as irreversible binding may lead to severe consequences, including death. For example, sarin gas binds covalent bonds irreversibly to the active site of the enzyme causing death on prolonged exposure [1]. The use of reversible acetylcholinesterase inhibitors has attracted particular attention, in particular for the treatment of Alzheimer-type dementia and has been the subject of extensive research and clinical investigation. Several
compounds (Fig. 1) have been approved for alleviating the symptoms of the disease [3]. However, synthetic AChE inhibitors such as physostigmine, tacrine and donepezil have been reported to have adverse effects, such as hepatotoxicity and gastrointestinal complaints. Indeed, it has proved difficult to develop compounds to exclusively inhibit AChE in the brain without effecting other organs, or even other biochemical processes.

Numerous plant extracts have been investigated for their potential to treat cognitive disorders and neurodegenerative diseases. Galantamine was the first compound isolated from a plant source that was found to possess powerful AChE inhibitor activity, and although it was not without its secondary effects it is in clinical use. As such there is interest in the development of new AChE inhibitors and among these non-alkaloid compounds, including polyphenols have emerged as promising candidates. Polyphenols are an ubiquitous group of plant metabolites with \( \sim 10,000 \) structures identified to date. Although traditionally regarded as non-nutrients because of their astringent taste or cause of browning, polyphenols and other food phenolics has been the subject of increasing interest due to their health benefits [4]. The present review addresses the emerging evidence regarding the potential for polyphenols to act as acetylcholinesterase inhibitors. In doing so, we will highlight the function of AChE before assessing the direct inhibitory capacity of polyphenols and whether diets rich in these compounds might have beneficial effects in alleviating specific disorders associated with AChE activity.

2. Acetylcholinesterase enzyme

Isolated from *Torpedo californica*, the acetylcholinesterase enzyme (Tc-AChE) is a protein with 501 amino acid residues having an ellipsoid shape with dimensions \( \sim 45 \text{ Å} \times 60 \text{ Å} \times 65 \text{ Å} \) (for a complete description see [5]). The active site (detailed in Fig. 2), is located in a deep and narrow gorge of 20 Å that becomes larger in the bottom, where the catalytic site is located. The structure of the active site was determined from studies carried out on protein extracted from *Torpedo californica* and *Electrophorus eel*, which are structurally homologous to that of the vertebrate [6] and human enzyme [7]. From these studies it was evident that the active site has two sub-sites, the esteratic (E5), comprising the catalytic site and the anionic...
The catalytic triad of this enzyme, located in the esteratic subsite, is composed by Ser200, His440 and Glu327 in TcAChE [5], or Ser203, His447 and Glu334 in mammals [8]. The anionic sub-site is the site known to bind the choline moiety and comprises Trp330, Phe330, and Glu199 in TcAChE [9]. The esteratic sub-site is equivalent to the serine-binding site in other serine proteases. The Ser200 residue initiates the catalytic process [10], and the imidazole function of His participates in this process through a mechanism involving acid-base catalysis [1].

Besides these two sub-sites, the active site also contains another location known as Peripheral Anionic Site (PAS), at the entrance of the gorge, which comprises another set of aromatic residues, Tyr72, Tyr124, Trp279, Trp286, and Glu285, together with Asp74 (in human AChE), or Tyr70, Tyr121, Trp279, Trp334, Asp125 (in TcAChE). This site is where the inhibitor molecules are “selected” to modulate the catalytic activity of the enzyme [11] and several studies have revealed that binding to the PAS sub-site could change the conformation of the active site, thus inhibiting enzyme activity [12]. It has been proposed that the indole moiety of Trp286 (Trp279 in TcAChE) might interact via stacking, aromatic-aromatic or via π-cation attractions, along with the involvement of the carboxylate of Asp74 (in charge-charge or H-bond interactions) [12] to confer inhibitory activity. All these residues participate in the inhibition process, by preventing substrates from entering the catalytic site by blockage of the catalytic gorge [7].

Aromatic ring moieties are suggested to be involved in the selection and stabilization of the positive charge of the quaternary group in the acetylcholine through π-electrons stabilization in a process called “aromatic guidance”. The effect of AChE inhibition on ACh can be depicted from the scheme shown in Fig. 3.
3. Acetylcholinesterase and its inhibition: Relevance to human disease

As referred above, acetylcholinesterase inhibitors have several clinical applications, namely in facilitating the digestive process, as well as in disorders such as Myasthenia gravis, Glaucoma and Alzheimer’s disease. The inhibition of AChE localized in the neuromuscular junctions [13, 14], increases muscle contraction thus helping the digestive activity by enhancing gastrointestinal motility [15, 16]. Via a similar mechanism, AChE inhibitors present in neuromuscular junctions are also used to reverse neuromuscular block after anaesthesia [17]. AChE inhibitors were first used in 1932 in the Myasthenia gravis disease to improve patient conditions [18], and in 1938 the process was approved and applied to treat people suffering from this disease [19]. Later in 1960, antibodies against acetylcholine receptors were produced in this disorder and such immunosuppressive methods are still in use [20]. AChE inhibitors have also been used to treat Glaucoma [2, 21], where their use reduces pathology by decreasing the intra-ocular pressure that results in death of retinal ganglion cells. In this case, inhibitors lead to structural protection of retinal ganglion cells from the ocular hypertension.

Loss of acetylcholine signalling in the brain correlates with the severity of Alzheimer’s disease (AD), the most common form of dementia in elderly people. There are several AChE inhibitors that have been designed and clinically approved to inhibit the breakdown of acetylcholine in the brain, thus leading to increases in cholinergic neurotransmitter activity and for alleviating the symptoms of Alzheimer’s disease. AD is a complex biochemical process [22, 23] for which there is no cure. The administration of cholinesterase inhibitors is based on the cholinergic hypothesis, briefly meaning that the loss of cholinergic function in the central nervous system is associated with the cognitive decline in AD (reviewed in [24]). This loss in cholinergic function leads to a gradual loss of functional neurons in the brain of elderly people [25]. Many factors may be associated/correlated with this loss of cholinergic activity, including amyloid-β peptide (Aβ) formation and tau protein aggregation (reviewed in [26]), excessive transition metals [27] and oxidative stress [28]. Interestingly, AChE inhibitors have been observed to affect the "amyloid cascade" [29], in which insoluble Aβ-peptide is deposited in the brain [30]. However, AChE may also be involved in the formation of Aβ-peptides [31] accelerating its formation and it appears that the PAS of the enzyme is crucial for this activity [32]. Although surgical interventions have been used effectively to treat patients suffering from AD by improving cerebral blood flow (CBF) [33], presently invasive surgical intervention is not an option in all patients and other mechanisms are also not wholly effective [34]. Thus there is still a requirement for additional drug treatments such as AChE inhibitors.

4. Structural features defining the inhibition of acetylcholinesterase

There are only a few studies that define the molecular mechanisms of acetylcholinesterase inhibition by the polyphenols. Docking studies carried out with the potent inhibitor donepezil (Dnp) and Tr-AChE have shed some light on this mechanism [35]. Donepezil fits inside the gorge extending from the anionic sub-site at the bottom, to the peripheral anionic site at the entrance. The compound has a dimethoxyindanone moiety, which orients itself towards the entrance establishing bonds with the PAS of the enzyme, more precisely with Trp279 (Fig. 1c) and a strong connection with this residue appears crucial for inhibition activity [35]. The benzyl ring is oriented towards the bottom of the gorge making π−π stacking interactions with the Trp546, occupying the binding site for the quaternary group of acetylcholine, preventing its interaction with the catalytic triad. Another example of the inhibitory orientation within the AChE gorge came from rivastigmine docking studies. Here, the carbamyl moiety of the drug is covalently linked to the Tr-AChE active site and the (1-dimethylamino)ethylphenoxo leaving group is oriented towards the anionic site [36]. Furthermore, studies with choline derivatives of caffeic acid (Fig. 4) have revealed that the presence of a methyl group increases the inhibitory activity [37], as one of the methoxy groups orients towards the Trp779 residue at the PAS sub-site, as is also the case with donepezil.

Flavonoid orientation inside the enzyme gorge also looks similar to that presented by donepezil. Flavonoids have an aromatic ring (B-ring) (see Fig. 5), which contains −OH groups that establish bonds with the PAS of the enzyme. Flavonoids appear not to induce modifications in the ternary structure of the enzyme, meaning that the inhibition process occurs due to the
blockage of the entrance to the active site. Quercetin (Fig. 6a) has been found to establish several hydrogen bonds with the amino acid residues at the anionic sub-site. The carbonyl moiety in C ring and –OH group in C5 position of the A-ring establishes hydrogen bonds with Tyr133, whilst C3 –OH group in the C ring hydrogen bonds with the Trp86 residue in the anionic site. Finally the –OH group of the phenyl side (B-ring) shows hydrogen bonding with residues in the PAS sub-site [39]. Such H-binding confers flavonoids with enhanced AChE inhibitor activity relative to other phenolic compounds like caffeic acid (Fig. 6b) and rosmarinic acid (Falé PL, Ascensão L, Serralheiro MLM, Haris PI, unpublished data). The existence of an –OH group in C3 position appears to be crucial in increasing inhibition activity. Indeed, docking studies with flavonoids indicate that amino acid binding in the active gorge is more favourable with a greater number of hydrogen bonds [39]. The interactions established between the C3 –OH group and Trp86 may explain why rutin and kaempferol 3-O-β-D-galactoside that have this –OH group conjugated, show lower activity than quercetin [39]. Interactions between the Trp279 at the PAS sub-site have also been reported with the aromatic ring of choline ester of 3,4-dimethoxycinnamic acid (Fig. 6c) [37].

In summary, it seems that phenolic compounds having structural motifs similar to caffeic acid are capable of fitting into the gorge of the active site of AChE by positioning the aromatic ring into the PAS sub-site, with the exception of phenolics like 2-hydroxy-6-[10′(Z)-heptadeceny]benzoic acid, in which the aromatic ring orients towards the anionic sub-site [12]. Flavonoids that possess a free OH-group at C3 position are more inhibitory compared to their C3 –OH glycosylated counterparts and those having no C3 –OH group, such as luteolin and apigenin. Flavonoids, as caffeic acid, orientate within the pocket with their B ring facing the PAS site. However, one should bear in mind that most phenolic compounds are metabolised during absorption in the gastrointestinal tract and again in the liver, leading to O-methylated, sulphated and glucuronide forms. These metabolites, along with those produced in the large intestine via the actions of the bacteria, are chemically different from the forms found in food and those predominantly tested for AChE inhibitory activity to date. Future work in this area must continue to consider and investigate the actions of these metabolites that reach the circulatory system and other target organs, as they may not inhibit in the same manner.

5. Acetylcholinesterase inhibitors from natural sources

Despite issues regarding absorption and metabolism and precise mechanisms of action in vivo, the screening for acetylcholinesterase inhibitors found in plants is valid in highlighting those compounds with the most promise of biological activity. For example, galantine (Fig. 1a) is an alkaloid isolated from Galanthus spp. [40] that is now used clinically. The discovery of this compound provoked the search for new compounds that might be useful as acetylcholinesterase inhibitors for clinical use. Ethno-pharmacological approaches and bioassay-guided isolation have proven effective in identifying potential AChE inhibitors from plant sources. Mukherjee et al. [41] highlights the plants and/or their active constituents reported to have AChE inhibitory activity (% inhibition; concentration), with the most significant inhibitors thought to be alkaloids and a few glycosides. Other plants with reported CNS activity (used in traditional South African medicine to treat various mental conditions)
Fig. 6. Structures of different phenolics compounds with AChE inhibition: 1 flavonoid (quercetin) 1 phenolic acid (caffeic acid), 1 caffeic acid choline ester (choline ester of 3,4-dimethoxy cinnamic acid), phloroglucinol and a phloroglucinol-based polyphenol (6,6-bieckol).

are also rich sources of such alkaloids, although many of these are known to be toxic [42]. Many phenolic compounds have also been investigated for their CNS function, including a wide range of flavonoids. For example, a number are reported to exert sedative/anxiolytic effects via direct binding to GABA<sub>A</sub> receptors in animal model studies, as is the case of 6-hydroxyflavone [43] and a tri-substituted benzoflavone moiety from *Passiflora incarnata* [44]. Oroxylin A (5,7-dihydroxy-6-methoxyflavone), a flavonoid found in the roots of *Scutellaria baicalensis*, has also been shown to exert cognitive enhancement via antagonistic GABA<sub>A</sub> receptor binding and resultant cholinergic up-regulation [45]. Furthermore, a recent study indicated that trans-resveratrol exerts an anti-depressant-like action via monoamine oxidase inhibition and resultant increase in levels of 5-HT, DA, and noradrenaline in select brain areas [46].
6. Polyphenols as acetylcholinesterase inhibitors

Plant phenolics are well known to play crucial roles in plant ecology and physiology and play important roles in the prevention of many chronic diseases. Perhaps the oldest medical application of phenolic compounds was their use as antiseptics and sunscreens, due to the effective absorption of the UV-B radiation (between 280 and 315 nm) by phenolic groups [4, 47]. More recently polyphenols such as flavonoids have been investigated for their acetylcholinesterase inhibitory activity [48], along with other phenolic compounds [39, 48–53]. For example, the phenolic extracts of 12 traditional medicinal plants from southern Africa have been assessed for their acetylcholinesterase inhibitory potential [54], with five plants showing good cholinesterase inhibitory activities, but identification of these active compounds was not indicated. Furthermore, the non-aqueous extracts of seven medicinal plants commonly used for the treatment of pain-related ailments in South Africa have been assessed for their anti-inflammatory, anticholinesterase and antioxidant properties [55], with alkaloids and phenolics being suggested as the bioactive components. During a screening for AChE inhibitors in 180 medicinal plants, various active polyphenols were highlighted, including tiliroside, 3-methoxyquercetin, quercitrin and quercetin [51], whilst galangin was identified in a separate study [52]. Recently various papers have appeared concerning the evaluation of AChE inhibitory activity in medicinal plants (Table 1), many of which have also been used traditionally to promote memory and inhibit neurological disorders [56–60]. However, whilst these studies highlight various plant extracts of possessing AChE inhibitor activity, in many cases the specific compounds responsible for inhibitory activity are not precisely determined.

Despite this the effects of curcumin, found in turmeric, (–)-epigallocatechin-3-gallate (EGCG), the main active phenolic compound in green tea, and resveratrol have all been proposed as having actions on the brain [63, 64]. With regards to the AChE inhibition, the flavanone naringenin, a major flavonoid present in citrus has been shown to exert AChE inhibitory activity in vitro and anti-amnesic activity in vivo [65]. The flavonol quercetin [67] has not been tested for its inhibitory activity in vivo but also appears to influence cerebral blood flow and cholinergic dysfunction in brain [66]. The authors suggested that consumption of a diet rich in quercetin may prevent dementia associated with vascular and neurodegenerative disorders, such as Alzheimer’s disease. However, whilst various (poly)phenols have been proposed to inhibit AChE activity (Table 2) future work is required to establish whether these compounds reach the brain and directly affect AChE activity.

7. Screening plant extracts for acetylcholinesterase inhibition

The previous section highlighted work with some single polyphenols that showed promising AChE inhibitory activity. However, a significant amount of work has also been conducted using foods extracts to screen for potential foods with the view to isolating novel AChE inhibitors. Multiple phenolic compounds coexist in foods (for an overview of dietary flavonoids, see [38]). Fruits, vegetables, beverages (tea, juice, wine) and several herbs contain an array of polyphenols that exhibit a range of biological activities and are thought to contribute to the beneficial effects of fruit and vegetable intake. In recent years there has been a great deal of interest in the action of such polyphenols against neurodegenerative diseases, such as Alzheimer’s disease. Many plants have been used traditionally as therapeutic effects against dementia

<table>
<thead>
<tr>
<th>Plant</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agrimonia pilosa ledebourii</td>
<td>[51]</td>
</tr>
<tr>
<td>Mentha aquatica</td>
<td>[62]</td>
</tr>
<tr>
<td>Buddleja davidi</td>
<td></td>
</tr>
<tr>
<td>Scutellaria taxa</td>
<td>[57]</td>
</tr>
<tr>
<td>Salvia taxa</td>
<td>[60, 70]</td>
</tr>
<tr>
<td>Juniperus sp.</td>
<td>[71]</td>
</tr>
<tr>
<td>Eucalyptus excelsior</td>
<td>[72]</td>
</tr>
<tr>
<td>Calendula sp.</td>
<td>[73]</td>
</tr>
<tr>
<td>Larvecoccus officinalis</td>
<td>[74]</td>
</tr>
<tr>
<td>Catharanthus roseus</td>
<td>[78]</td>
</tr>
<tr>
<td>Ficus fulva var.</td>
<td></td>
</tr>
<tr>
<td>Mentha pulegium</td>
<td>[80]</td>
</tr>
<tr>
<td>Rosmarinus officinalis</td>
<td></td>
</tr>
<tr>
<td>Taxus brevifolia</td>
<td></td>
</tr>
<tr>
<td>Cymbopogon schoenanthus</td>
<td>[81]</td>
</tr>
<tr>
<td>Camellia sinensis</td>
<td>[82, 88]</td>
</tr>
<tr>
<td>Hypericum sp.</td>
<td>[85]</td>
</tr>
<tr>
<td>Pseudocitrus polyanthos</td>
<td>[87]</td>
</tr>
<tr>
<td>Plectranthus barbatus</td>
<td>[100]</td>
</tr>
</tbody>
</table>

Table 1: Plant extracts with AChE inhibitory activity
Table 2
Natural phenolic compounds as AChE inhibitors

<table>
<thead>
<tr>
<th>Compound</th>
<th>Source</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiliroside</td>
<td>Agrimonia pilosa ledebouriet</td>
<td>[51]</td>
</tr>
<tr>
<td>3-methoxyquercetin</td>
<td>Agrimonia pilosa ledebouriet</td>
<td>[51]</td>
</tr>
<tr>
<td>Quercetin</td>
<td>Many fruits, vegetables, beverages</td>
<td>[51, 66]</td>
</tr>
<tr>
<td>Quercitrin</td>
<td>Traditional Chinese medicines</td>
<td>[52]</td>
</tr>
<tr>
<td>Linarin</td>
<td>Mentha arvensis; Buddleja davidi</td>
<td>[62]</td>
</tr>
<tr>
<td>Curcumin</td>
<td>Tumeric</td>
<td>[63]</td>
</tr>
<tr>
<td>Reovirinol</td>
<td>Red wine</td>
<td>[63]</td>
</tr>
<tr>
<td>Naringenin</td>
<td>Citrus junius</td>
<td>[65]</td>
</tr>
<tr>
<td>Chlorogenic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rutin</td>
<td>Hypericum species</td>
<td>[85]</td>
</tr>
<tr>
<td>Hyperoside</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoquercitrin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sativonic acid B</td>
<td>Rady Salvia miltiorrhiza</td>
<td>[61]</td>
</tr>
<tr>
<td>Gallocatechins: EC, EGC, EGCG</td>
<td>Camellia sinensis; Diospyros kaki</td>
<td>[63, 88, 93]</td>
</tr>
<tr>
<td>Phlorotannins: 6,6-bieckol, diphtllolethohydroxycarmalol</td>
<td>Marine brown algae (Phaeophyta)</td>
<td>[95]</td>
</tr>
<tr>
<td>Rosmarinic acid</td>
<td>Plectranthus barbatus</td>
<td>[100]</td>
</tr>
</tbody>
</table>

and as part of these studies have also been investigated for their acetylcholinesterase inhibitory activity in vitro (Table 1). These include, Scutellaria L taxa and Salvia taxa [57, 69, 70] and herbal coffees [75, 76], with results proving promising but not conclusive. One of the reasons for this may be that the majority of anti-acetylcholinesterase tests performed in vitro were conducted on the organic extracts of these plants and may not be fully representative of possible effects after consumption of whole foods or beverages. Again, the active compounds were not identified and no account of absorption and metabolism of compounds contained within these extracts were made.

Similar shortcomings apply to in vivo trials, where an extract of blueberry (methanol, acetic acid and water: 25:1:24) showed effects on cognitive performance, brain oxidative status and acetylcholinesterase activity in mice [77]. As most polyphenols in blueberry would be expected to be more soluble in an aqueous medium, the influence of an aqueous extract, or whole blueberry may be more representative of the biological affects in vivo. Whilst there are also physiological shortcomings of experiments testing aqueous extracts from traditional medicinal plants for AChE inhibition in vivo [61, 78–84], they do at least highlight the presence of potential interesting compounds within these complex extract mixtures. Indeed, Hernandez et al. [85] postulated that the active AChE inhibitors in Hypericum were phenolics such as chlorogenic acid, rutin, hyperoside, isoquercitrin and quercetin, which was confirmed by determining the AChE inhibitory activity of the pure compounds. Again, before firm conclusions can be drawn of the significance of these findings, the absorption and metabolism of these components needs to be factored in.

A few in vivo studies have also evaluated the effect of polyphenol-rich extracts on acetylcholinesterase activity. Intervention with a water-soluble extract of propolis led to significant inhibition of hippocampal AChE activity along with cognitive improvements that may be mediated by apigenin, kaempferol and luteolin [86]. In addition, an aqueous extract of Pseudoranthemum palatiferum, a polyphenol-rich tea used predominantly in Thailand, has also been shown to inhibit AChE in the brain (hippocampus), serum and red blood cells in rats [87]. An extract of the more widely consumed green tea (0.5%; containing 60% flavanols, most prominently (−)-epigallocatechin-3-gallate) was effective in enhancing learning and memory in aged rats and also the selective inhibition of acetylcholinesterase [88]. These results are in agreement with other studies in scopolamine-treated mice, where tea polyphenols significantly reversed cognitive deficits and exhibited a dramatic inhibitory effect on AChE activity [89].

Whilst not yet investigated AChE inhibition activity, berry extracts containing high levels of anthocyanins [90] and cocoa flavanols [91, 92] have also been shown to exert promising effects against age-related cognitive decrements in rodents and humans by limiting
neurodegeneration and/or preventing normal or abnor-
mal deteriorations in cognitive performance [93]. The
mechanism of action of flavonoid-rich foods might be
partly mediated by actions on brain AChE activity,
as has been suggested for other, more complex fla-
vanols such as tannins [94]. Moreover, marine brown
algae (Phaeophyta) contain a variety of phloroglucinol-
based polyphenols, known as phlorotannins (Figs. 6d
and e) and have been proposed to have health
beneficial properties [95]. The 6.6-bi-ciekol from I. oka-
murae (Phaeophyceae) has been shown to express
potent AChE inhibitory effects, [96], although as a
non-competitive inhibitor. As highlighted earlier, a sig-
nificant amount of additional work is required in order
to fully assess the potential for such foods and polyphen-
ols to act as AChE inhibitors, although this activity
remains a possible mechanism of action of polyphenols
from these foods in vivo.

8. Open issues and concluding remarks

A survey of medicinal plants and their extracts
in order to evaluate their medicinal and therapeutic
potential have revealed that there are many polyphen-
ols that have a potential to act as AChE inhibitors.
Additionally, other sources of such compounds exist
such as from agro-industrial and forest residues [97].
Extractable polyphenols from different types of veget-
able biomass are of special interest as they are readily
available and cheap [98]. Recent studies performed on
the water extracts of olive pomace and carob kibbles
(two biomass residues from food processing and agro-
industrial transformation), indicate that both extracts
have significant acetylcholinesterase inhibitory activity.
AChE activity after feeding aqueous extracts or whole
extracts/foods. Furthermore, when conducting in vitro
studies designed to establish the active components,
the issue of bioavailability and biotransformation of
these compounds and their metabolites must be con-
sidered and applied (for a review on cellular uptake and
metabolism of flavonoids refer to [99]). Indeed, results
have indicated that such metabolism is important in
defining actual activity [100, 101]. For example, AChE
inhibitory activity of Plectranthus barbatus decoction,
consumed as an herbal tea was retained after gastric
juice digestion but reduced around 50% after pancreatic
digestion [100]. Rosmarinic acid, the main
phenolic compound found in this extract, was detected
in the brain of rats, where acetylcholinesterase activ-
ity was decreased by 30% in comparison with control
animals [102]. These results indicate that rosmarinic
acid may permeate the blood brain barrier and act as
an acetylcholinesterase inhibitor in the brain.

As it is currently impossible to assess brain AChE
inhibitory activity in human studies further animal
studies are needed in order to establish which phenolic
compounds or their metabolites exert AChE inhibitory
activity in vivo. However, in parallel to these further
investigations of which foods are capable of ame-
liorating cognitive function should also take place.
It is worthwhile to conduct epidemiological studies
regarding polyphenol intake and the progression of
neurodegenerative diseases that require a lengthy incu-
bation time before clinical manifestation [103] and
variation between the geographical distributions of var-
ious neurological disorders should be compared with
food polyphenolic composition data across various
countries and ethnicities. Indeed, Nurk et al. report
a positive relationship between the intake of vari-
ous plant foods and cognitive performance in elderly
people in a cross-sectional study in Norway (The
Hordaland Health Study), concluding that a diet rich
in plant foods, particularly vegetables or the combina-
tion of fruit and vegetables, is associated with better
performance in several cognitive abilities in a dose-
dependent manner [104]. Whilst it is not possible to
attribute these effects to AChE inhibitory activity of
deliver polyphenols, such studies would further build
the evidence base for the activity of such foods and
diets.

Lastly, phytochemical-rich foods also contain com-
ounds other than polyphenols, such as terpenes and
alkaloids that may also be effective AChE inhibitors
either alone or in synergy with phenolics. In vivo
References


Kryger G, Silman I, Sussman JL. Structure of acetyl-


Kryger G, Silman I, Sussman JL. Structure of acetyl-


[94] FMLHM, FMLHM, FMLHM, FMLHM, FMLHM. FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLHM, FMLH